Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp94 | Diabetes Therapy | ECE2018

Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-center Randomized Controlled Trial

Jeon Jae-Han , Lee In-Kyu , Jeong Ji-Yun

The advent of Web-based patient management technologies, including Web-based messaging, video conferencing, remote monitoring of vital signs, and Web-based educational programs, has resulted in the recognition that telemedicine may benefit diabetic patients with limited access to healthcare providers and/or a high burden of disease. In this regard, 24-week prospective multi-center randomized controlled trial involved 338 adult patients with type 2 diabetes at four university h...

ea0056p521 | Endocrine Disruptors | ECE2018

Deleterious effect of low-dose persistent organic pollutants on insulin secretion in pancreatic β-cell

Lee In-Kyu , Jeon Jae-Han , Ha Chae-Myeong

Low-dose persistent organic pollutants (POPs), especially organochlorine pesticides (OCPs) and polychlorinated biphenyls (PCBs), have emerged as a new risk factor for type 2 diabetes. We evaluated whether chronic exposure to low-dose POPs affects insulin secretory function of β-cells in humans and in vitro cells. Serum concentrations of OCPs and PCBs were measured in 200 adults without diabetes. Mathematical model-based insulin secretion indices were estimated by...

ea0099p345 | Pituitary and Neuroendocrinology | ECE2024

Expression pattern of select cell proliferation and apoptotic markers in non-functioning pituitary adenomas predictive of tumour growth/recurrence: a pilot project

Hebb Andrea , Croul Sidney , Han Jae , Massoud Emad , Tramble Lisa , Imran Syed , Clarke David

Introduction: While there is a significant risk of recurrence in nonfunctioning pituitary adenoma (NFPA) after surgery, it is challenging to predict which NFPAs will recur based solely on routine histopathology. To better understand markers of recurrence, we assessed the established tumor markers linked to aggressive tumor behavior including X-linked IAP (XIAP), the most potent inhibitor of the apoptosis protein family, vascular epithelial growth factor (VEGF) which facilitate...

ea0063p533 | Diabetes, Obesity and Metabolism 2 | ECE2019

A novel oral pyruvate dehydrogenase kinase 4 inhibitor ameliorates various spectrum of metabolic diseases in mice

Jeon Jae-Han , Lee In-Kyu , Choi Yeon-Kyung , Park Keun-Gyu , Kim Na-Young , Park Sung Don , Ahn Jin Hee , Kim Min-Ji

Pyruvate dehydrogenase kinase 4 (PDK4) activation is associated with metabolic diseases including hyperglycemia, insulin resistance, allergies, and cancer. We report here a new series of allosteric PDK4 inhibitor modified from hit anthraquinone. A novel PDK4 inhibitor, namely compound 8c, improved glucose tolerance in diet-induced obese mice. PDH activity in muscle and liver was enhance d by compound 8c treatment. Given the importance of PDK4 in immune cells including mast cel...

ea0041ep435 | Diabetes (to include epidemiology, pathophysiology) | ECE2016

Relation between uric acid and lipid profiles in patients with type 2 diabetes

Kim Eui-Hyun , Bae Kwi-Hyun , Jeon Jae-Han , Choi Yeon-Kyung , Kim Mi-Kyung , Kim Hye-Soon , Park Keun-Gyu , Seo Hyun-Ae

Aims: High level of uric acid is known to associate with stroke, coronary artery disease and metabolic syndrome. Some epidemiologic studies suggested that high uric acid level is connected with dyslipidemia. However, this relationship was not examined in type 2 diabetic patients. This study was conducted to investigate the association between serum uric acid level and lipid profiles in type 2 diabetic patients.Methods: A total of 972 type 2 diabetes pati...